Huawei Hengyuan Biotech
华卫恒源
Huawei Hengyuan Biotech
Biotech/Healthcare
Huawei Hengyuan develops in vitro production of Sertoli cells with immune-privileged properties using cell reprogramming technology. Target applications include autoimmune diseases such as rheumatoid arthritis, assisted reproductive treatment such as Sertoli-cell-only syndrome, chronic diseases…
Latest round: Series A (2025)
Source: ChinaBulls — chinabulls.com
Last updated 2025-06-01
Funding history
Request access to view this section.
Investors
Request access to view this section.
HQ & website
Request access to view this section.
Tags
Request access to view this section.